Investing in AI feels like a gamble.
You need a reality check
before you write the check.
Introducing ARIA™
A clinical-grade risk audit for AI companies.
Introducing ARIA™
A clinical-grade risk audit for AI companies.
"In health AI, the hype makes it hard to see clearly.
By the time the validation gaps surface, the money is already in.
With ARIA™, we can thoroughly evaluate a company's technical, commercial, and regulatory risk before capital is committed, and before liabilities surface."
Dr. Amir Lahav">
Ask Before You Invest
VC Firms
Fast AI diligence
on new early-stage companies
- Can Claude do it better?
- Is this another point solution?
- What was excluded from the deck?
Private Equity
Deep AI diligence
on companies you already own
- Are the algorithms still improving?
- Was the validation done right?
- Asset at exit, or write-down?
Family Offices
Independent judgment with
no in-house specialist
- Still relevant in five years?
- Are any of the claims inflated?
- What's the liability if it's wrong?
How ARIA™ Works
A clinical validation audit for AI companies:
1. Data Integrity & Bias
Most AI failures trace back to one thing: flawed training data. It leads to models that fail approval and tank valuations, and without independent dataset verification, you’re funding write-offs, not exits.
- Investigates whether the AI foundation is solid
- Traces AI data sources through publications, pilot trials, supplementary records, and validation studies
- Audits 15+ quality dimensions, including selection bias, fairness gaps, labeling integrity, and ground truth validity
✓ Go/No-go decision
Confidence to invest or walk away before capital burns
✓ Risk mitigation
Hidden vulnerabilities that standard diligence overlooks
2. Algorithm Performance & Drift
Impressive performance on a pitch deck can be misleading without context, and demos rarely survive contact with the real world. Without validating the testing protocols, you’re trusting results that collapse on deployment.
- Analyzes scientific integrity, data contamination, and leakage
- Spots performance failures before regulators or patients do
- Verifies AI works beyond demos on messy, unfriendly, real-world data
✓ Investment protection
Methodological flaws and sloppy algorithms caught before they become liabilities
✓ Invest in the right companies
Complete clinical evidence, not just the highlight reel
3. Validation Gap Analysis
Cutting corners in clinical validation threatens your investment. It leads to regulatory failure, market rejection, and safety liabilities. By the time they surface, the money is already in.
- Validates claims against published literature and real-world data
- Identifies data analysis flaws and validation gaps
- Reviews safeguards and false-positive rates
✓ Investment protection
Early visibility into validation gaps that could delay market entry or create liabilities
✓ Competitive advantage
Companies with genuinely robust evidence that others overlook
4. Safety & Guardrails Inspection
AI without proper guardrails is a ticking time bomb. It produces dangerous outputs and fails silently. The result is patient harm, regulatory action, and reputational damage that can sink the company.
- Inspects abstention thresholds, confidence scoring, and escalation triggers
- Reviews human-in-the-loop protocols and override capabilities
- Pressure-tests edge cases and failure scenarios to expose safety vulnerabilities
✓ High-stakes assurance
Verified guardrails at critical clinical decision points
✓ Investment protection
Costly failures prevented before they eliminate portfolio value
5. Portfolio Foresight & Future-Proofing
Your companies might be solving today’s problems with outdated methods, or solving problems that won’t exist by the time they reach the market. Without foresight, you’re holding a depreciating asset.
- Guides portfolio companies through system upgrades, market shifts, and obsolescence threats
- Monitors AI performance to catch model drift, emerging biases, and degradation before they become costly
- Tracks regulatory shifts before they become enforcement actions
✓ Future-proof while capturing upside
Visibility into where AI is heading, early enough to act on it
✓ Maximize exit value
Portfolio companies that stay competitive, compliant, and acquisition-ready as AI evolves
Close
Close
Close